Homelessness, drug overdose Other
Conditions
Interventions
Participants are randomized using a telephone randomization service provided by the University of Birmingham
The intervention group receive weekly visits to the patient in their place of residence o
Sponsors
NHS Greater Glasgow and Clyde
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult 2. Homeless 3. Drug overdose in the past 6 months
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 13/02/2024: 1. Unable to give written informed consent 2. Living in a residential or community-based rehabilitation facility which has direct access to in-house medical and nursing care Previous exclusion criteria: Critically unwell/under the influence and unable to comprehend the request
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 13/02/2024: Achievement of criteria for progression to RCT: 1. Recruitment rate recorded as 100 participants consenting to participate by 4 months 2. Data collection: at least 80% of participants with data collected (baseline, 6 and 9 months follow up) 3. Intervention adherence: at least 60% of participants in the PHOENIx group receiving the intervention 4. Retention: at least 60% of participants remaining in the study (receiving in-person or telephone follow-up assessment at 6 and 9 months post-randomisation) 5. Improvement in the rate of presentation to Emergency Departments and overdoses collected by researchers from health and social care records at 6 or 9 months follow up Previous primary outcome measures: Achievement of criteria for progression to RCT: recruitment rate recorded as 100 participants consenting to participate by 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 13/02/2024: Assessed by researchers as close as possible to planned 6 and 9 months after baseline: 1. The number of participants with, and time to first, overdose or hospitalisation measured using health and social care records 2. The number of participants receiving prescribed treatment for physical or mental health and problem drug use measured using health records 3. The number of treatments per participant measured using health records 4. Health-related quality of life measured using Euro Qol-Visual Analogue Scale (EQ-VAS) which forms part of the self-rated EQ-5D-5L 5. Healthcare contacts measured using health records 6. Missed appointments measured using health records 7. Work and impact of self-management on functioning and well-being measured using the Patient Experience with Treatment and Self-management (PETS) measure 8. Number of primary health care contacts measured using clinical records 9. Number of missed and attended out-patient appointments measured using clinical records 10. Frailty measured using Fried’s adapted frailty phenotype 11. Anxiety/depression measured using Patient Health Questionnaire-4 (PHQ-4) 12. Breathlessness measured using modified Medical Research Council (MRC) breathlessness scale 13. Peak flow rate measured using a peak flow meter 14. Participant-reported injecting drug use 15. Attempted suicide measured using self-report and from clinical records 16. Self-harm measured using self-report 17. Welfare entitlements measured using self-report 18. Social prescribing measured using self-report 19. Tenancy type measured using self-report Previous secondary outcome measures: Rate of overdose measured by collecting data from NHS Greater Glasgow and Clyde clinical records from baseline until the date of follow-up (8-11 months after baseline assessment) | — |
Countries
Scotland, United Kingdom
Outcome results
None listed